CN1520821A - 头孢尼西抗菌组合物 - Google Patents

头孢尼西抗菌组合物 Download PDF

Info

Publication number
CN1520821A
CN1520821A CNA2003101098085A CN200310109808A CN1520821A CN 1520821 A CN1520821 A CN 1520821A CN A2003101098085 A CNA2003101098085 A CN A2003101098085A CN 200310109808 A CN200310109808 A CN 200310109808A CN 1520821 A CN1520821 A CN 1520821A
Authority
CN
China
Prior art keywords
cnc
sbt
taz
cefonicid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2003101098085A
Other languages
English (en)
Other versions
CN1247200C (zh
Inventor
叶澄海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Priority to CN 200310109808 priority Critical patent/CN1247200C/zh
Publication of CN1520821A publication Critical patent/CN1520821A/zh
Application granted granted Critical
Publication of CN1247200C publication Critical patent/CN1247200C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种抗β－内酰胺酶抗菌素复方制剂，具体为头孢尼西及其盐和舒巴坦及其盐或他唑巴坦及其盐组成的复方制剂。该复方制剂中头孢尼西及其盐和舒巴坦及其盐或他唑巴坦及其盐的重量比范围为0.5∶1至10∶1；头孢尼西及其盐和舒巴坦及其盐的优选重量比范围为0.5∶1至6∶1，最佳重量比为1∶1，头孢尼西及其盐和他唑巴坦及其盐的优选重量比范围为1∶1至6∶1，最佳重量比为2∶1。本发明较头孢尼西抗菌谱更广、抗菌作用更强。

Description

头孢尼西抗菌组合物
技术领域
本发明涉及一种抗β-内酰胺酶抗菌素复方制剂，具体涉及头孢尼西及其盐和舒巴坦及其盐或他唑巴坦及其盐组成的复方制剂。
背景技术
头孢类抗菌药物已广泛地应用于临床，为人类的健康起到了积极作用。同时，由于临床上长期、广泛的使用，细菌对头孢类抗生素的耐药性问题日益严重。细菌对头孢类抗生素耐药的主要机制为产生特异性的β-内酰胺酶(β-lactmases)分解药物，其中包括由染色体介导的I型头孢菌素酶和由质粒介导的超广谱β-内酰胺酶。为了克服产β-内酰胺酶细菌所造成的临床耐药性感染，研制头孢类抗生素与β-内酰胺酶抑制剂的复方制剂具有重要的临床意义。
由于目前临床上的大量使用，原来对头孢尼西敏感的致病菌出现了耐药菌株，即使加长用药时间或者增大用药剂量也达不到预期治疗效果。
目前，国内外尚未见有将头孢尼西及其盐与舒巴坦及其盐或他唑巴坦及其盐组成复方制剂，作为新药上市和临床应用的报道。
发明内容
本发明的目的是克服上述现有技术的不足，提供一种头孢尼西及其盐与舒巴坦及其盐或他唑巴坦及其盐组成的复方制剂，相对于头孢尼西而言，该复方制剂抗菌谱更广、抗菌作用更强。
本发明采用的技术方案是：一种抗β-内酰胺酶抗菌素复方制剂，该复方制剂中含有头孢尼西及其盐和舒巴坦及其盐或他唑巴坦及其盐，所述头孢尼西及其盐和舒巴坦及其盐或他唑巴坦及其盐的重量比范围为0.5∶1至10∶1。
所述抗β-内酰胺酶抗菌素复方制剂中，所述头孢尼西及其盐和舒巴坦及其盐的优选重量比范围为0.5∶1至6∶1，所述头孢尼西及其盐和他唑巴坦及其盐的优选重量比范围为1∶1至6∶1。
所述抗β-内酰胺酶抗菌素复方制剂中，所述头孢尼西及其盐和舒巴坦及其盐的最佳重量比为1∶1，所述头孢尼西及其盐和他唑巴坦及其盐的最佳重量比为2∶1。
所述抗β-内酰胺酶抗菌素复方制剂的制备方法按已知的粉针剂或冻干粉针剂工艺程序操作进行即可。
采用本发明提供的技术方案，较头孢尼西而言，注射用抗β-内酰胺酶抗菌素复方制剂抗菌谱更广、抗菌作用更强。
当所述抗β-内酰胺酶抗菌素复方制剂中头孢尼西与舒巴坦的比例为1∶1时，该复方制剂对产酶株的体外抗菌和杀菌活性明显优于头孢尼西，其中，对金黄色葡萄球菌(产酶)、表皮葡萄球菌(产酶)、肺炎球菌(产酶)、大肠埃希氏菌(产酶)、肺炎克雷伯氏菌(产酶)和铜绿假单胞菌(产酶)MIC50分别为4、8、2、8、8和32μg/ml，MIC90分别为8、64、8、64、32和128μg/ml，对金黄色葡萄球菌(产酶)、大肠埃希菌(产酶)和铜绿假单胞菌(产酶)MBC/MIC值范围均为4-8、4-8和8倍；头孢尼西对金黄色葡萄球菌(产酶)、表皮葡萄球菌(产酶)、肺炎球菌(产酶)、大肠埃希氏菌(产酶)、肺炎克雷伯氏菌(产酶)和铜绿假单胞菌(产酶)MIC50分别为64、128、32、32、128和≥256μg/ml，MIC90分别为256、256、64、256、≥256和≥256μg/ml，对金黄色葡萄球菌(产酶)、大肠埃希氏菌(产酶)和铜绿假单胞菌(产酶)MBC/MIC值范围分别为4、8和≥2。
当所述抗β-内酰胺酶抗菌素复方制剂中头孢尼西与他唑巴坦的比例为2∶1时，该复方制剂对产酶株的体外抗菌和杀菌活性明显优于头孢尼西，其中，对金黄色葡萄球菌(产酶)、表皮葡萄球菌(产酶)、肺炎球菌(产酶)、大肠埃希氏菌(产酶)、肺炎克雷伯氏菌(产酶)和铜绿假单胞菌(产酶)MIC50分别为4、4、1、8、4和16μg/ml，MIC90分别为64、64、8、32、16和128μg/ml，对金黄色葡萄球菌(产酶)、大肠埃希氏菌(产酶)和铜绿假单胞菌(产酶)MBC/MIC值范围均为4-8、8和8倍；头孢尼西对金黄色葡萄球菌(产酶)、表皮葡萄球菌(产酶)、肺炎球菌(产酶)、大肠埃希氏菌(产酶)、肺炎克雷伯氏菌(产酶)和铜绿假单胞菌(产酶)MIC50分别为64、128、32、32、128和≥256μg/ml，MIC90分别为256、256、64、256、≥256和≥256μg/ml，对金黄色葡萄球菌(产酶)、大肠埃希氏菌(产酶)和铜绿假单胞菌(产酶)MBC/MIC值范围分别为4-8、4-8和≥4。
具体实施方式
实施例1：制备头孢尼西钠和舒巴坦钠复方制剂
将0.5g头孢尼西钠无菌粉和1g舒巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例2：制备头孢尼西钠和舒巴坦钠复方制剂
将0.5g头孢尼西钠无菌粉和0.5g舒巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例3：制备头孢尼西钾和舒巴坦钠复方制剂
将0.5g头孢尼西钾无菌粉和0.25g舒巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例4：制备头孢尼西钾和舒巴坦钠复方制剂
将0.5g头孢尼西无菌粉和0.125g舒巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例5：制备头孢尼西钠和舒巴坦钠复方制剂
将0.5g头孢尼西钠无菌粉和0.1g舒巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例6：制备头孢尼西钾和舒巴坦钠复方制剂
将0.5g头孢尼西钾无菌粉和0.05g舒巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例7：制备头孢尼西和舒巴坦钠复方制剂
将0.5g头孢尼西无菌粉和0.5g舒巴坦钾无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例8：制备头孢尼西钠和舒巴坦钾复方制剂
将0.5g头孢呋辛钠无菌粉和0.5g舒巴坦钾无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例9：制备头孢尼西钾和舒巴坦钾复方制剂
将0.5g头孢尼西钾无菌粉和0.5g舒巴坦钾无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
试验实施例1：头孢尼西和舒巴坦复方制剂体外抗菌和杀菌试验
用无菌水或灭菌生理盐水进行溶解并按有效药物含量配制并稀释至所需的药物浓度，头孢尼西钠/舒巴坦钠的有效药物配比均为1∶2，1∶1，2∶1，4∶1，8∶1，10∶1。实验所采用的菌株均为临床分离株，每株来源于不同的病人。
试验方法：
1.1最低抑菌浓度(MIC)的测定
吸取适量稀释好的不同浓度的药物置于无菌平面皿中，加入恒温于55℃左右的灭菌培养基，混匀冷却制成药物平板。将培养好的试验菌用无菌水稀释至所需浓度(一般为107CFU/ml左右)，采用多点接种仪接至不同浓度的药物平板，接种量约为104～105CFU/点。试验菌于37℃恒温培养24小时观察结果，并记录MIC值。
1.2最低杀菌浓度(MBC)的测定
采用肉汤倍比稀释活菌计数法，即在倍比稀释的药物溶液中加入一定浓度的菌液，混合后于37℃恒温培养24小时，先测出MIC值，再依次将未见细菌生长的澄清的各管培养物分别吸出0.1ml，进行平板活菌计数，其中菌落数少于5个的平板所对应的最低药物浓度即为该药物的MBC值。
试验结果：
2.1最低抑菌浓度(MIC)
由表1-1可知，头孢尼西和舒巴坦复方制剂中头孢尼西与舒巴坦的重量比为0.5∶1至10∶1时，体外抗菌活性较好，头孢尼西与舒巴坦的优选重量比为0.5∶1至6∶1。头孢尼西和舒巴坦复方制剂(CXM/SBT＝1∶1)对产酶株的体外抗菌活性较头孢尼西强，对非产酶株的体外抗菌活性与头孢尼西相似，其中对金黄色葡萄球菌(产酶)、表皮葡萄球菌(产酶)、肺炎球菌(产酶)、大肠埃希氏菌(产酶)、肺炎克雷伯氏菌(产酶)和铜绿假单胞菌(产酶)MIC50分别为4、8、2、8、8和32μg/ml，MIC90分别为8、64、8、64、32和128μg/ml；头孢尼西对金黄色葡萄球菌(产酶)、表皮葡萄球菌(产酶)、肺炎球菌(产酶)、大肠埃希氏菌(产酶)、肺炎克雷伯氏菌(产酶)和铜绿假单胞菌(产酶)MIC50分别为64、128、32、32、128和≥256μg/ml，MIC90分别为256、256、64、256、≥256和≥256μg/ml。
2.2最低杀菌浓度(MBC)
由表1-2可知，头孢尼西和舒巴坦复方制剂(CXM/SBT＝1∶1)对产酶株的体外杀菌活性较头孢尼西强，对非产酶株的体外杀菌活性与头孢尼西相似，其中对金黄色葡萄球菌(产酶)、大肠埃希氏菌(产酶)和铜绿假单胞菌(产酶)MBC/MIC值范围均为4-8、4-8和8倍；头孢尼西对金黄色葡萄球菌(产酶)、大肠埃希氏菌(产酶)和铜绿假单胞菌(产酶)MBC/MIC值范围分别为4、8和≥2。
实施例10：制备头孢尼西和他唑巴坦复方制剂
将0.5g头孢呋辛无菌粉和0.5g他唑巴坦无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例11：制备头孢尼西钠和他唑巴坦复方制剂
将0.5g头孢尼西钠无菌粉和0.25g他唑巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例12：制备头孢尼西钾和他唑巴坦复方制剂
将0.5g头孢呋辛钾无菌粉和0.125g他唑巴坦无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例13：制备头孢尼西和他唑巴坦钠复方制剂
将0.5g头孢尼西无菌粉和0.1g他唑巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例14：制备头孢尼西钠和他唑巴坦钠复方制剂
将0.5g头孢尼西钠无菌粉和0.05g他唑巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例15：制备头孢尼西钾和他唑巴坦钠复方制剂
将0.5g头孢尼西钾无菌粉和0.25g他唑巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例16：制备头孢尼西和他唑巴坦钾复方制剂
将0.5g头孢尼西无菌粉和0.25g他唑巴坦钠无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例17：制备头孢尼西钠和他唑巴坦钾复方制剂
将0.5g头孢尼西钠无菌粉和0.25g他唑巴坦钾无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
实施例18：制备头孢尼西钾和他唑巴坦钾复方制剂
将0.5g头孢尼西钾无菌粉和0.25g他唑巴坦钾无菌粉混合，按已知的粉针剂或冻干粉针剂工艺程序操作。
试验实施例2：头孢尼西和他唑巴坦复方制剂体外抗菌和杀菌试验
用无菌水或灭菌生理盐水进行溶解并按有效药物含量配制并稀释至所需的药物浓度，头孢尼西/他唑巴坦的有效药物配比为1∶1、2∶1、4∶1、8∶1、10∶1。试验用菌株及试验方法同试验实施例1。
试验结果：
1.1最低抑菌浓度(MIC)
由表2-1可知，头孢尼西与他唑巴坦的复方制剂中头孢尼西与他唑巴坦的重量比为1∶1至10∶1时，体外抗菌活性较好，头孢尼西与他唑巴坦的优选重量比为1∶1至6∶1。注射用头孢尼西/他唑巴坦(CNC/TAZ＝2∶1)对产酶株的体外抗菌活性较头孢尼西强，对非产酶株的体外抗菌活性与头孢尼西相似，其中金黄色葡萄球菌(产酶)、表皮葡萄球菌(产酶)、肺炎球菌(产酶)、大肠埃希氏菌(产酶)、肺炎克雷伯氏菌(产酶)和铜绿假单胞菌(产酶)MIC50分别为4、4、1、8、4和16μg/ml，MIC90分别为64、64、8、32、16和128μg/ml；头孢尼西对金黄色葡萄球菌(产酶)、表皮葡萄球菌(产酶)、肺炎球菌(产酶)、大肠埃希氏菌(产酶)、肺炎克雷伯氏菌(产酶)和铜绿假单胞菌(产酶)MIC50分别为64、128、32、32、128和≥256μg/ml，MIC90分别为256、256、64、256、≥256和≥256μg/ml。
1.2最低杀菌浓度(MBC)
由表2-2可知，注射用头孢尼西/他唑巴坦(CNC/TAZ＝2∶1)对产酶株的体外杀菌活性较头孢尼西强，对非产酶株的体外抗菌活性与头孢尼西相似。注射用头孢尼西/他唑巴坦(CNC/TAZ＝2∶1)对金黄色葡萄球菌(产酶)、大肠埃希氏菌(产酶)和铜绿假单胞菌(产酶)MBC/MIC值范围均为4-8、8和8倍；头孢尼西对金黄色葡萄球菌(产酶)、大肠埃希氏菌(产酶)和铜绿假单胞菌(产酶)MBC/MIC值范围分别为4-8、4-8和≥4。
表1-1头孢尼西(CNC)与头孢尼西/舒巴坦(CNC/SBT)体外抗菌活性(MIC≤16判定为敏感)
                                                                 MIC(μg/ml)
细菌      株      药物              ≤16     32     64    ≥128  MIC50  MIC9   MIC范围      敏感率(％)
          数                                   株数                      0
                  CNC                3       6      6     15     64      256     16～≥256    10
金黄色            CNC/SBT(1∶2)      1       8      6     15     64      128     16～≥256    3.3
葡萄球菌          CNC/SBT(1∶1)      27      1      1     1      4       8       1～128       90
(产酶)    30      CNC/SBT(2∶1)      27      1      1     1      4       16      1～128       90
                  CNC/SBT(4∶1)      27      1      1     1      8       16      2～128       90
                  CNC/SBT(8∶1)      13      6      8     3      32      64      4～≥256     43.3
                  CNC/SBT(10∶1      7       6      6     11     64      128     16～≥256    23.3
                  CNC                22      5      2     1      2       32      0.25～128    73.3
金黄色            CNC/SBT(1∶2)      18      7      2     3      8       64      2～128       60
葡萄球菌          CNC/SBT(1∶1)      19      6      3     2      4       64      1～128       63.3
          30      CNC/SBT(2∶1)      19      5      4     2      4       64      0.5～128     63.3
                  CNC/SBT(4∶1)      21      4      5     0      4       64      0.5～64      70
                  CNC/SBT(8∶1)      19      8      3     0      2       32      0.25～64     63.3
                  CNC/SBT(10∶1      22      6      2     0      2       32      0.5～64      73.3
                  CNC                0       3      6     11     128     256     32～≥256    0
表皮葡            CNC/SBT(1∶2)      4       6      4     6      32      128     8～≥256     20
萄球菌            CNC/SBT(1∶1)      13      3      3     1      8       64      1～128       65
(产酶)    20
                  CNC/SBT(2∶1)      11      4      3     2      8       64      2～128       55
                  CNC/SBT(4∶1)      13      5      2     0      8       32      1～64        65
                  CNC/SBT(8∶1)      5       6      4     5      32      128     4～≥256     25
                  CNC/SBT(10∶1      2       4      4     10     64      128     8～≥256     10
                  CNC                15      4      0     1      4       16      1～128       75
                  CNC/SBT(1∶2)      9       4      5     2      16      64      4～128       45
表皮葡
                  CNC/SBT(1∶1)      15      3      2     0      8       32      0.5～64      75
萄球菌    20
                  CNC/SBT(2∶1)      13      4      2     1      8       64      1～64        65
                  CNC/SBT(4∶1)      13      5      2     0      8       32      1～64        65
                  CNC/SBT(8∶1)      14      4      1     1      4       32      0.25～128    70
                  CNC/SBT(10∶1      15      3      1     1      4       32      1～128       75
                  CNC                2       3      4     1      32      64      16～128      20
肺炎链            CNC/SBT(1∶2)      1       4      4     1      32      64      8～128       10
球菌              CNC/SBT(1∶1)      7       3      0     0      2       8       0.5～32      70
(产酶)    10      CNC/SBT(2∶1)      6       4      0     0      4       8       1～32        60
                  CNC/SBT(4∶1)      6       3      1     0      4       32      1～64        60
                  CNC/SBT(8∶1)      5       1      3     1      16      64      8～128       50
                  CNC/SBT(10∶1      4       2      3     1      32      64      16～128      40
                  CNC                10      0      0     0      2       8       0.25～16     100
                  CNC/SBT(1∶2)      5       3      2     0      16      64      2～64        50
肺炎链            CNC/SBT(1∶1)      9       1      0     0      4       16      1～32        90
球菌      10      CNC/SBT(2∶1)      9       1      0     0      4       32      1～32        90
                  CNC/SBT(4∶1)      7       3      0     0      4       16      0.5～32      70
                  CNC/SBT(8∶1)      9       1      0     0      2       8       0.0625～32   90
                  CNC/SBT(10∶1      10      0      0     0      2       4       0.0625～8    100
续表1-1
                                                                  MIC(μg/ml)
细菌      株      药物               ≤16    32     64     ≥128  MIC50    MIC90   MIC范围      敏感率
数                                             株数                                                (％)
                  CNC                5       5      3      7      32        256      8～≥256      25
大肠埃            CNC/SBT(1∶2)      6       5      4      5      32        128      4～≥256      30
希氏菌            CNC/SBT(1∶1)      13      3      3      1      8         64       1～128        65
(产酶)    20      CNC/SBT(2∶1)      11      4      2      3      8         64       2～128        55
                  CNC/SBT(4∶1)      12      6      1      1      8         32       2～128        60
                  CNC/SBT(8∶1)      9       5      4      2      16        64       2～128        45
                  CNC/SBT(10∶1)     5       3      4      6      32        128      8～≥256      25
                  CNC                26      6      0      0      2         32       0.5～32       81.3
                  CNC/SBT(1∶2)      17      8      5      2      8         64       2～128        53.1
大肠埃            CNC/SBT(1∶1)      23      7      1      1      4         32       1～128        71.9
希氏菌    32      CNC/SBT(2∶1)      27      3      0      0      4         8        1～32         84.4
                  CNC/SBT(4∶1)      27      3      0      0      4         8        1～32         84.4
                  CNC/SBT(8∶1)      28      2      0      0      2         8        0.25～32      87.5
                  CNC/SBT(10∶1)     29      1      0      0      2         8        0.25～32      90.6
                  CNC                0       0      0      18     ≥256     ≥256    128～≥256    0
铜绿假            CNC/SBT(1∶2)      0       0      4      14     128       ≥256    64～≥256     0
单胞菌            CNC/SBT(1∶1)      7       2      3      6      32        128      4～≥256      38.9
(产酶)    18      CNC/SBT(2∶1)      7       2      2      7      32        128      8～≥256      38.9
                  CNC/SBT(4∶1)      0       0      8      10     128       ≥256    64～≥256     0
                  CNC/SBT(8∶1)      0       0      0      18     ≥256     ≥256    128～≥256    0
                  CNC/SBT(10∶1)     0       0      0      18     ≥256     ≥256    128～≥256    0
                  CNC                12      3      1      0      8         32       2～64         75
                  CNC/SBT(1∶2)      2       5      5      4      64        ≥256    16～≥256     12.5
铜绿假            CNC/SBT(1∶1)      12      3      1      0      16        32       4～64         75
单胞菌    16      CNC/SBT(2∶1)      11      3      2      0      16        32       2～64         68.8
                  CNC/SBT(4∶1)      8       4      3      0      16        64       1～64         50
                  CNC/SBT(8∶1)      11      0      1      0      8         16       2～64         68 8
                  CNC/SBT(10∶1)     10      1      1      0      8         32       1～64         62.5
                  CNC                0       0      6      10     128       ≥256    64～≥256     0
肺炎克            CNC/SBT(1∶2)      0       0      7      9      128       ≥256    64～≥256     0
雷伯氏            CNC/SBT(1∶1)      11      4      0      1      8         32       2～128        68.8
菌        16      CNC/SBT(2∶1)      10      3      2      1      16        64       8～≥256      62.5
(产酶)            CNC/SBT(4∶1)      8       2      3      3      16        128      4～≥256      50
                  CNC/SBT(8∶1)      0       5      3      8      64        ≥256    32～≥256     0
                  CNC/SBT(10∶1)     0       3      4      9      128       ≥256    32～≥256     0
                  CNC                19      4      2      0      4         32       1～64         76
肺尖克            CNC/SBT(1∶2)      14      5      4      2      16        64       2～≥256      56
雷伯氏            CNC/SBT(1∶1)      15      4      6      0      4         64       0.5～64       60
菌        25      CNC/SBT(2∶1)      16      5      4      0      4         32       2～64         64
                  CNC/SBT(4∶1)      16      5      4      0      8         64       1～64         64
                  CNC/SBT(8∶1)      18      5      2      0      4         16       0.5～64       72
                  CNC/SBT(10∶1)     20      3      2      0      4         32       1～64         80
续表1-1
                                                                MIC(μg/ml)
细菌      株      药物               ≤16   32    64    ≥128   MIC50   MIC90  MIC范围      敏感率
数                                            株数                                            (％)
                  CNC                2      4     3     1       32       64      16～256      20
小动杆菌          CNC/SBT(1∶2)      3      3     3     1       16       64      4～128       30
                  CNC/SBT(1∶1)      10     0     0     0       1        4       0.5～8       100
(产酶)
          10      CNC/SBT(2∶1)      10     0     0     0       1        4       0.25～4      100
                  CNC/SBT(4∶1)      9      1     0     0       4        16      1～32        90
                  CNC/SBT(8∶1)      6      2     2     0       16       64      4～64        60
                  CNC/SBT(10∶1)     5      2     2     1       16       64      4～128       50
                  CNC                11     1     0     0       8        16      1～32        91.7
                  CNC/SBT(1∶2)      4      3     2     3       32       128     4～256       33.3
不动杆菌          CNC/SBT(1∶1)      11     1     0     0       8        16      0.5～32      91.7
          12      CNC/SBT(2∶1)      10     2     0     0       8        32      2～32        83.3
                  CNC/SBT(4∶1)      9      2     1     0       16       32      2～64        75
                  CNC/SBT(8∶1)      8      3     0     0       8        32      2～32        66.7
                  CNC/SBT(10∶1)     11     1     0     0       8        16      1～32        91.7
                  CNC                3      3     4     0       8        64      8～64        30
产气杆菌          CNC/SBT(1∶2)      9      1     0     0       4        8       4～32        90
(产酶)            CNC/SBT(1∶1)      10     0     0     0       1        4       0.25～16     100
          10      CNC/SBT(2∶1)      10     0     0     0       1        8       0.25～16     100
                  CNC/SBT(4∶1)      10     0     0     0       2        8       0.5～16      100
                  CNC/SBT(8∶1)      8      1     1     0       8        32      2～64        80
                  CNC/SBT(10∶1)     6      1     3     0       8        64      4～64        60
                  CNC                10     0     0     0       2        4       0.125～16    100
                  CNC/SBT(1∶2)      8      1     1     0       8        32      2～64        80
产气杆菌          CNC/SBT(1∶1)      10     0     0     0       4        8       0.5～16      100
          10      CNC/SBT(2∶1)      10     0     0     0       4        8       0.5～16      100
                  CNC/SBT(4∶1)      10     0     0     0       4        16      1～16        100
                  CNC/SBT(8∶1)      10     0     0     0       2        8       0.5～16      100
                  CNC/SBT(10∶1)     10     0     0     0       2        4       0.5～16      100
                  CNC                10     0     0     0       1        4       0.25～4      100
福氏痢疾          CNC/SBT(1∶2)      10     0     0     0       2        16      0.5～64      100
杆菌(产           CNC/SBT(1∶1)      10     0     0     0       0.5      1       0.125～4     100
酶)       10      CNC/SBT(2∶1)      10     0     0     0       1        8       0.125～8     100
                  CNC/SBT(4∶1)      10     0     0     0       0.5      8       0.25～8      100
                  CNC/SBT(8∶1)      10     0     0     0       1        8       0.5～8       100
                  CNC/SBT(10∶1)     10     0     0     0       0.5      4       0.25～4      100
                  CNC                10     0     0     0       0.0625   1       0.0313～2    100
                  CNC/SBT(1∶2)      10     0     0     0       0.5      4       0.25～16     100
福氏痢疾          CNC/SBT(1∶1)      10     0     0     0       0.125    2       0.0625～2    100
杆菌      10      CNC/SBT(2∶1)      10     0     0     0       0.125    4       0.0625～4    100
                  CNC/SBT(4∶1)      10     0     0     0       0.25     4       0.0625～4    100
                  CNC/SBT(8∶1)      10     0     0     0       0.125    2       0.0625～4    100
                  CNC/SBT(10∶1)     10     0     0     0       0.0625   1       ≤0.0313～2  100
续表1-1
                                                                 MIC(μg/ml)
细菌      株    药物               ≤16    32     64     ≥128   MIC50     MIC90   MIC范围         敏感率(％)
          数                                 株数
                CNC                0       0      0      16      ≥256      ≥256    128～≥256      0
阴沟肠杆        CNC/SBT(1∶2)      0       0      0      16      ≥256      ≥256    128～≥256      0
菌(产酶)        CNC/SBT(1∶1)      3       3      4      6       64         128      16～≥256       18.8
          16    CNC/SBT(2∶1)      3       4      3      6       64         ≥256    16～≥256       18.8
                CNC/SBT(4∶1)      0       4      3      9       128        ≥256    32～≥256       0
                CNC/SBT(8∶1)      0       0      0      16      ≥256      ≥256    128～≥256      0
                CNC/SBT(10∶1)     0       0      0      16      ≥256      ≥256    128～≥256      0
                CNC                14      4      2      0       8          32        2～64          70
                CNC/SBT(1∶2)      9       4      5      2       32         64        4～128         45
阴沟肠杆        CNC/SBT(1∶1)      13      3      3      1       8          64        2～128         65
菌        20    CNC/SBT(2∶1)      14      4      1      1       8          32        1～128         70
                CNC/SBT(4∶1)      18      2      0      0       8          16        2～32          90
                CNC/SBT(8∶1)      15      2      3      0       8          64        2～64          75
                CNC/SBT(10∶1)     16      2      2      0       8          32        1～64          80
                CNC                10      0      0      0       0.0313     0.125     ≤0.0313～1    100
                CNC/SBT(1∶2)      10      0      0      0       1          8         0.5～8         100
伤寒沙门        CNC/SBT(1∶1)      10      0      0      0       0.0625     0.5       ≤0.0313～1    100
氏菌      10    CNC/SBT(2∶1)      10      0      0      0       0.0625     0.5       ≤0.0313～1    100
                CNC/SBT(4∶1)      10      0      0      0       0.0625     1         ≤0.0313～1    100
                CNC/SBT(8∶1)      10      0      0      0       0.0313     0.25      ≤0.0313～1    100
                CNC/SBT(10∶1)     10      0      0      0       0.0313     0.25      ≤0.0313～1    100
                CNC                                                                   0.0625
金葡            CNC/SBT(1∶2)                                                         1
ATCC2592        CNC/SBT(1∶1)                                                         0.25
3         1     CNC/SBT(2∶1)                                                         0.25
                CNC/SBT(4∶1)                                                         0.125
                CNC/SBT(8∶1)                                                         0.0625
                CNC/SBT(10∶1)                                                        0.0625
                CNC                                                                   4
大肠杆菌        CNC/SBT(1∶2)                                                         16
ATCC2592        CNC/SBT(1∶1)                                                         8
2         1     CNC/SBT(2∶1)                                                         16
                CNC/SBT(4∶1)                                                         8
                CNC/SBT(8∶1)                                                         4
                CNC/SBT(10∶1)                                                        4
                CNC                                                                   8
绿脓杆菌        CNC/SBT(1∶2)                                                         64
ATCC2785        CNC/SBT(1∶1)                                                         8
3         1     CNC/SBT(2∶1)                                                         8
                CNC/SBT(4∶1)                                                         8
                CNC/SBT(8∶l)                                                         4
                CNC/SBT(10∶1)                                                        8
表1-2头孢尼西/舒巴坦(CNC/SBT＝1∶1)与头孢尼西(CNC)的最低杀菌浓度(MBC)
                                    MIC(μg/ml)          MBC(μg/ml)
               株
细菌                 药物                                              MBC/MIC
               数                 第一株    第二株    第一株   第二株
                      CNC         32        16        128      64      4
S.auresE      2
                      CNC/SBT     4         8         32       32      4～8
                      CNC         4         2         16       8       4～8
S.aures        2
                      CNC/SBT     4         4         32       16      4～8
                      CNC         32        32        256      256     8
E.coliE       2
                      CNC/SBT     8         8         32       64      4～8
                      CNC         2         4         8        32      4～8
E.coli         2
                      CNC/SBT     8         4         16       32      2～8
                      CNC         128       128       ≥256    ≥256   ≥2
P.aeruginosaE 2
                      CNC/SBT     16        8         64       64      4～8
                      CNC         4         4         32       32      8
P.aeruginosa   2
                      CNC/SBT     8         16        32       64      4
S.aures               CNC         0.0625              0.5              8
               1
(ATCC25923)           CNC/SBT     0.25                1                4
E.coli                CNC         4                   16               4
               1
(ATCC25922)
                      CNC/SBT     8                   32               4
P.aeruginosa          CNC         8                   64               8
               1
(ATCC27853)
                      CNC/SBT     8                   32               4
表2-1头孢尼西(CNC)与头孢尼西/他唑巴坦(CNC/TAZ)体外抗菌活性
                                     (MIC≤16判定为敏感)
                                                                    MIC(μg/ml)
细菌      株       药物              ≤16     32      64     ≥128  MIC50 MI     MIC范围       敏感率(％)
          数                                                               C90
                                                 株数
                   CNC               3        6       6      15     64     256    16～≥256     10
金黄色             CNC/TAZ(1∶1)     8        4       6      2      4      64     2～256        60
葡萄球菌           CNC/TAZ(2∶1)     21       5       3      1      4      64     0.5～128      70
(产酶)    30       CNC/TAZ(4∶1)     19       6       3      2      4      64     1～128        63.3
                   CNC/TAZ(8∶1)     11       5       6      8      32     128    4～≥256      36.7
                   CNC/TAZ(10∶1     7        6       5      12     64     256    8～≥256      23.3
                   CNC               22       5       2      1      2      32     0.25～128     73.3
金黄色             CNC/TAZ(1∶1)     24       4       2      0      8      32     1～64         80
葡萄球菌           CNC/TAZ(2∶1)     24       2       3      1      4      64     0.5～128      80
          30       CNC/TAZ(4∶1)     23       5       1      2      4      32     0.25～128     76.7
                   CNC/TAZ(8∶1)     21       6       3      0      2      16     0.125～64     70
                   CNC/TAZ(10∶1     24       4       2      0      2      16     0.25～64      80
                   CNC               0        3       6      11     128    256    32～≥256     0
表皮葡             CNC/TAZ(1∶1)     10       3       5      2      16     64     4～256        50
萄球菌             CNC/TAZ(2∶1)     12       3       3      2      4      64     0.5～128      60
(产酶)    20       CNC/TAZ(4∶1)     11       3       4      2      8      64     1～128        55
                   CNC/TAZ(8∶1)     7        4       4      5      32     128    16～≥256     35
                   CNC/TAZ(10∶1     3        5       4      8      64     128    8～≥256      15
                   CNC               15       4       0      1      4      16     1～128        75
                   CNC/TAZ(1∶1)     15       3       1      1      8      32     2～128        75
表皮葡             CNC/TAZ(2∶1)     15       3       2      0      8      32     0.5～64       75
萄球菌    20       CNC/TAZ(4∶1)     13       2       3      2      8      64     1～128        65
                   CNC/TAZ(8∶1)     15       3       1      1      4      32     0.5～128      75
                   CNC/TAZ(10∶1     18       1       1      0      4      16     0.5～64       90
                   CNC               2        3       4      1      32     64     16～128       20
肺炎链             CNC/TAZ(1∶1)     6        2       1      1      8      64     2～128        60
球菌               CNC/TAZ(2∶1)     10       0       0      0      1      8      0.25～16      100
(产酶)    10
                   CNC/TAZ(4∶1)     9        1       0      0      1      16     0.125～32     90
                   CNC/TAZ(8∶1)     5        2       2      1      8      64     1～128        50
                   CNC/TAZ(10∶1     4        1       3      1      16     64     4～128        40
                   CNC               10       0       0      0      2      8      0.25～16      100
                   CNC/TAZ(1∶1)     6        2       2      0      8      64     2～64         60
肺炎链
                   CNC/TAZ(2∶1)     9        1       0      0      2      8      0.5～32       90
球菌      10
                   CNC/TAZ(4∶1)     9        1       0      0      4      8      0.5～32       90
                   CNC/TAZ(8∶1)     9        1       0      0      2      16     0.25～32      90
                   CNC/TAZ(10∶1     10       0       0      0      2      16     0.25～16      100
续表2-1
                                                                        MIC(μg/ml)
细菌      株      药物               ≤16      32       64      ≥128   MIC50  MIC90   MIC范       敏感率(％)
          数                                                                             围
                                                  株数
                  CNC                5         5        3       7       32      256      8～≥       25
大肠              CNC/TAZ(1∶1)      10        2        6       2       16      64       2～≥       50
埃希              CNC/TAZ(2∶1)      15        5        1       1       8       32       2～128      75
氏菌      20      CNC/TAZ(4∶1)      12        4        3       1       8       64       1～128      60
(产酶)            CNC/TAZ(8∶1)      7         3        4       6       32      128      4～≥       35
                  CNC/TAZ(10∶1)     4         6        4       6       32      128      8～≥       20
                  CNC                26        6        0       0       2       32       0.5～2      81.3
                  CNC/TAZ(1∶1)      25        3        3       1       4       64       2～128      78.1
大肠              CNC/TAZ(2∶1)      27        2        2       1       4       32       0.5～12     84.4
埃希      32      CNC/TAZ(4∶1)      29        1        2       0       4       16       0.25～6     90 6
氏菌              CNC/TAZ(8∶1)      30        1        1       0       2       8        0.5～64     93.8
                  CNC/TAZ(10∶1)     29        1        2       0       2       16       0.25～6     90.6
                  CNC                0         0        0       18      ≥256   ≥256    128～≥     0
铜绿              CNC/TAZ(1∶1)      4         5        3       6       32      128      4～≥       22.2
假单              CNC/TAZ(2∶1)      9         2        3       4       16      128      2～≥       50
胞菌      18      CNC/TAZ(4∶1)      9         4        4       1       16      64       2～≥       50
(产酶)            CNC/TAZ(8∶1)      4         3        5       6       64      ≥256    8～≥       22.2
                  CNC/TAZ(10∶1)     2         3        2       11      ≥256   ≥256    16～≥      11.1
                  CNC                12        3        1       0       8       32       2～64       75
                  CNC/TAZ(1∶1)      9         4        2       1       16      64       2～256      56.3
铜绿              CNC/TAZ(2∶1)      12        2        1       1       8       64       1～128      75
假单      16      CNC/TAZ(4∶1)      11        2        1       1       8       64       0.5～12     68.8
胞菌              CNC/TAZ(8∶1)      13        2        1       0       16      32       1～64       81.3
                  CNC/TAZ(10∶1)     12        3        1       0       8       32       0.5～64     75
                  CNC                0         0        6       10      128     ≥256    64～≥      0
肺炎              CNC/TAZ(1∶1)      8         3        4       1       16      64       2～≥       50
克雷              CNC/TAZ(2∶1)      15        0        1       0       4       16       0.5～64     93.8
伯氏      16      CNC/TAZ(4∶1)      12        3        0       1       8       32       1～128      75
菌                CNC/TAZ(8∶1)      5         4        3       4       32      128      4～128      31.3
(产酶)            CNC/TAZ(10∶1)     2         3        3       8       64      ≥256    8～≥       12.5
                  CNC                19        4        2       0       4       32       1～64       76
肺炎              CNC/TAZ(1∶1)      18        3        3       1        8      64       1～128      72
克雷              CNC/TAZ(2∶1)      20        3        2       0        4      32       0.5～64     80
伯氏      25      CNC/TAZ(4∶1)      21        2        2       0        2      32       0.25～6     84
菌                CNC/TAZ(8∶1)      20        2        2       1        4      64       0.25～1     80
                  CNC/TAZ(10∶1)     20        3        1       1        4      16       0.5～12     80
续表2-1
                                                               MIC(μg/ml)
细菌      株      药物               ≤16    32    64    ≥128 MIC50  MIC90  MIC范围    敏感率
          数                                                                              (％)
                                               株数
                  CNC                2       4     3     1     32      64      16～256    20
不动杆菌          CNC/TAZ(1∶1)      9       0     1     0     4       16      1～64      90
                  CNC/TAZ(2∶1)      10      0     0     0     1       4       0.25～8    100
(产酶)
          10      CNC/TAZ(4∶1)      10      0     0     0     1       4       0.5～16    100
                  CNC/TAZ(8∶1)      6       2     1     1     16      64      2～128     60
                  CNC/TAZ(10∶1      5       1     2     2     16      128     4～256     50
                  CNC                11      1     0     0     8       16      1～32      91.7
                  CNC/TAZ(1∶1       9       3     0     0     16      32      2～32      75
不动杆菌          CNC/TAZ(2∶1)      10      1     1     0     8       32      2～64      83.3
          12      CNC/TAZ(4∶1)      10      1     1     0     16      32      1～64      83.3
                  CNC/TAZ(8∶1)      10      1     1     0     8       32      1～64      83.3
                  CNC/TAZ(10∶1)     11      1     0     0     4       32      0.5～32    91.7
                  CNC                3       3     4     0     8       64      8～64      30
产气杆菌          CNC/TAZ(1∶1)      9       1     0     0     2       8       1～32      90
(产酶)            CNC/TAZ(2∶1)      10      0     0     0     1       4       0.125～8   100
          10      CNC/TAZ(4∶1)      10      0     0     0     1       8       0.5～8     100
                  CNC/TAZ(8∶1)      9       0     1     0     4       16      1～64      90
                  CNC/TAZ(10∶1)     8       1     1     0     4       32      1～64      80
                  CNC                10      0     0     0     2       4       0.125～16  100
                  CNC/TAZ(1∶1)      8       1     1     0     4       32      1～64      80
产气杆菌          CNC/TAZ(2∶1)      10      0     0     0     4       16      0.25～16   100
          10      CNC/TAZ(4∶1)      9       1     0     0     4       16      0.5～32    90
                  CNC/TAZ(8∶1)      10      0     0     0     2       8       0.125～8   100
                  CNC/TAZ(10∶1      10      0     0     0     4       8       0.125～16  100
                  CNC                10      0     0     0     1       4       0.25～4    100
福氏痢疾          CNC/TAZ(1∶1)      10      0     0     0     0.5     4       0.0625～4  100
杆菌(产           CNC/TAZ(2∶1)      10      0     0     0     0.25    1       0.125～4   100
酶)       10      CNC/TAZ(4∶1)      10      0     0     0     0.5     4       0.125～8   100
                  CNC/TAZ(4∶1)      10      0     0     0     0.25    1       0.0313～2  100
                  CNC/TAZ(10∶1)     10      0     0     0     0.5     2       0.0313～4  100
                  CNC                10      0     0     0     0.0625  1       0.0313～2  100
                  CNC/TAZ(1∶1)      10      0     0     0     0.25    1       0.0313～4  100
福氏痢疾          CNC/TAZ(2∶1)      10      0     0     0     0.125   4       0.0625～4  100
杆菌      10      CNC/TAZ(4∶1)      10      0     0     0     0.125   2       0.0625～4  100
                  CNC/TAZ(4∶1)      10      0     0     0     0.125   4       0.125～4   100
                  CNC/TAZ(10∶1)     10      0     0     0     0.0313  0.5     ≤         100
续表2-1
                                                               MIC(μg/ml)
细菌      株        药物            ≤16   32    64    ≥128   MIC50    MIC90    MIC范围        敏感率
          数
                                                                                                  (％)
                                             株数
                 CNC                0      0     0     16      ≥256     ≥256     128～≥256     0
阴沟             CNC/TAZ(1∶1)      5      2     3     6       64        ≥256     8～≥256       31.3
肠杆             CNC/TAZ(2∶1)      8      3     4     1       16        64        4～128         50
菌(产      16    CNC/TAZ(4∶1)      8      2     2     4       16        128       4～≥256       50
酶)              CNC/TAZ(8∶1)      2      1     4     9       128       ≥256     8～≥256       12.5
                 CNC/TAZ(10∶1)     0      0     3     13      ≥256     ≥256     64～≥256      0
                 CNC                14     4     2     0       8         32        2～64          70
                 CNC/TAZ(1∶1)      15     3     2     0       8         32        4～64          75
阴沟             CNC/TAZ(2∶1)      15     2     2     1       16        64        4～128         75
肠杆      20     CNC/TAZ(4∶1)      14     2     3     1       16        64        2～128         70
菌               CNC/TAZ(8∶1)      16     2     2     0       8         32        1～64          80
                 CNC/TAZ(10∶1)     18     1     1     0       8         16        2～64          90
                 CNC                10     0     0     0       0.0313    0.125     ≤0.0313～1    100
                 CNC/TAZ(1∶1)      10     0     0     0       0.125     0.5       ≤0.0313～1    100
伤寒             CNC/TAZ(2∶1)      10     0     0     0       0.0625    0.25      ≤0.0313～1    100
沙门      10     CNC/TAZ(4∶1)      10     0     0     0       0.0625    0.5       ≤0.0313～1    100
氏菌             CNC/TAZ(8∶1)      10     0     0     0       0.0313    0.25      ≤0.0313～2    100
                 CNC/TAZ(10∶1)     10     0     0     0       0.0313    0.5       ≤0.0313～2    100
                 CNC                                                               0.0625
金葡             CNC/TAZ(1∶1)                                                     0.25
ATCC2            CNC/TAZ(2∶1)                                                     0.125
5923      1      CNC/TAZ(4∶1)                                                     0.125
                 CNC/TAZ(8∶1)                                                     0.0625
                 CNC/TAZ(10∶1)                                                    0.0625
                 CNC                                                               4
大肠             CNC/TAZ(1∶1)                                                     8
杆菌             CNC/TAZ(2∶1)                                                     8
ATCC2     1      CNC/TAZ(4∶1)                                                     4
5922             CNC/TAZ(8∶1)                                                     4
                 CNC/TAZ(10∶1)                                                    4
                 CNC                                                               8
绿脓             CNC/TAZ(1∶1)                                                     16
杆菌             CNC/TAZ(2∶1)                                                     4
ATCC2     1      CNC/TAZ(4∶1)                                                     4
7853             CNC/TAZ(8∶1)                                                     4
                 CNC/TAZ(10∶1)                                                    8
表2-2头孢尼西(CNC)与头孢尼西/他唑巴坦(CNC/IAZ＝2∶1)的最低杀菌浓度(MBC)
                                        MIC(μg/ml)       MBC(μg/ml)
                株
细菌                    药物                                            MBC/MIC
                                     第一株    第二株  第一株   第二株
                数
                        CNC           32       32      256      256     8
S.auresE
                 2
                        CNC/TAZ       4        8       32       32      4～8
                        CNC           2        4       16       16      4～8
S.aures          2
                        CNC/TAZ       4        4       32       16      4～8
                        CNC           16       8       128      16      2～8
E.coliE         2
                        CNC/TAZ       8        8       64       64      8
                        CNC           4        2       16       16      4～8
E.coli           2
                        CNC/TAZ       4        4       8        16      2～4
                        CNC           128      128     ≥256    ≥256   ≥2
P.aeruginosaE   2
                        CNC/TAZ       8        16      64       128     8
                        CNC           4        8       32       64      8
P.aeruginosa     2
                        CNC/TAZ       8        4       64       16      4～8
S.aures                 CNC           0.0625           0.5              8
                 1
(ATCC25923)             CNC/TAZ       0.125            0.5              4
E.coli                  CNC           4                32               8
                 1
(ATCC25922)             CNC/TAZ       8                32               4
P.aeruginosa            CNC           8                128              16
                 1
(ATCC27853)             CNC/TAZ       4                64               8

Claims (4)

1、一种抗β-内酰胺酶抗菌素复方制剂，其特征在于：所述抗β-内酰胺酶抗菌素复方制剂中含有头孢尼西及其盐和舒巴坦及其盐或他唑巴坦及其盐，所述头孢尼西及其盐和舒巴坦及其盐或他唑巴坦及其盐的重量比范围为0.5∶1至10∶1。
2、如权利要求1所述的抗β-内酰胺酶抗菌素复方制剂，其特征在于：所述头孢尼西及其盐和舒巴坦及其盐的重量比范围为0.5∶1至6∶1；所述头孢尼西及其盐和他唑巴坦及其盐的重量比范围为1∶1至6∶1。
3、如权利要求2所述的抗β-内酰胺酶抗菌素复方制剂，其特征在于：所述头孢尼西及其盐和舒巴坦及其盐的重量比为1∶1；所述头孢尼西及其盐和他唑巴坦及其盐的重量比为2∶1。
4、如权利要求1至3中任一权利要求所述的抗β-内酰胺酶抗菌素复方制剂，其特征在于：所述盐为碱金属盐。
CN 200310109808 2003-01-23 2003-12-23 头孢尼西抗菌组合物 Expired - Fee Related CN1247200C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200310109808 CN1247200C (zh) 2003-01-23 2003-12-23 头孢尼西抗菌组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN03113644 2003-01-23
CN03113644.3 2003-01-23
CN 200310109808 CN1247200C (zh) 2003-01-23 2003-12-23 头孢尼西抗菌组合物

Publications (2)

Publication Number Publication Date
CN1520821A true CN1520821A (zh) 2004-08-18
CN1247200C CN1247200C (zh) 2006-03-29

Family

ID=34314758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200310109808 Expired - Fee Related CN1247200C (zh) 2003-01-23 2003-12-23 头孢尼西抗菌组合物

Country Status (1)

Country Link
CN (1) CN1247200C (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101849949A (zh) * 2010-06-17 2010-10-06 深圳市新泰医药有限公司 一种头孢匹林钠和舒巴坦钠的组合物及其配比
CN102283847A (zh) * 2010-06-18 2011-12-21 广东立国制药有限公司 头孢尼西复方制剂及其制备方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101849949A (zh) * 2010-06-17 2010-10-06 深圳市新泰医药有限公司 一种头孢匹林钠和舒巴坦钠的组合物及其配比
CN101849949B (zh) * 2010-06-17 2012-05-23 深圳市新泰医药有限公司 一种头孢匹林钠和舒巴坦钠的组合物及其配比
CN102283847A (zh) * 2010-06-18 2011-12-21 广东立国制药有限公司 头孢尼西复方制剂及其制备方法

Also Published As

Publication number Publication date
CN1247200C (zh) 2006-03-29

Similar Documents

Publication Publication Date Title
CN1206995C (zh) 抗β－内酰胺酶抗菌素复方制剂
CN1038248C (zh) 双胍衍生物的制备方法
CN1840693A (zh) 革兰氏阴性细菌耐药基因检测方法及其专用芯片与试剂盒
CN1195859C (zh) 修饰化人源粒细胞－集落刺激因子及其制备方法
CN101061222A (zh) 编码甲基化儿茶素生物合成酶的基因
CN1160470C (zh) 研究体内蛋白质相互作用的方法
CN1030419A (zh) 6，7-二氢-吡唑并[1，5-a][1，3，5]三嗪-2-磺酰胺其制备方法和用其作为除莠剂和植物生长调节剂的用途
CN1192037C (zh) 用于由大肠杆菌向培养基中分泌来制备Leu－水蛭素的信号序列
CN1958794A (zh) 人肿瘤坏死因子相关凋亡诱导配体突变体编码cDNA及制备方法和应用
CN1279104C (zh) 纳米羟基磷灰石/聚乙烯醇复合水凝胶制备方法
CN1727343A (zh) 具有杀菌活性的取代噻吩并[3',2'∶5,6]吡啶并[4,3－d]嘧啶－4(3H)－酮及制备
CN1966678A (zh) 突变的木糖异构酶及其基因和用途
CN1730491A (zh) 猫ω干扰素及其编码基因与应用
CN1778930A (zh) 激发机体抗鸡球虫感染的融合基因及其编码蛋白与应用
CN1603299A (zh) 新型羧酸酯类除草剂
CN1520821A (zh) 头孢尼西抗菌组合物
CN1160459C (zh) 乳发酵短杆菌细胞色素bd型醌醇氧化酶基因
CN1827640A (zh) 血管生成抑制多肽及其制备方法和应用
CN87104023A (zh) 治疗细菌感染用的药物制剂
CN1891718A (zh) 融合免疫毒素ml－l－sec2和基因及其制备
CN1532282A (zh) 一种新型抗肠球菌多肽及其制备方法
CN1562040A (zh) 头孢呋辛与他唑巴坦的组合物
CN1954882A (zh) 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途
CN1875095A (zh) 重组微生物
CN1566159A (zh) 一种能特异杀死肿瘤细胞的基因工程重组蛋白

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SHENZHEN XINLITAI PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME OR ADDRESS: SALUBRIS PARMACEUTICALS

CP01 Change in the name or title of a patent holder

Address after: 1901 room 6007, exhibition center, 518040 Shennan Road, Guangdong, Shenzhen, Futian District

Patentee after: Shenzhen Salubris Pharmaceuticals Co., Ltd.

Address before: 1901 room 6007, exhibition center, 518040 Shennan Road, Guangdong, Shenzhen, Futian District

Patentee before: Xinlitai Pharmaceutical Industry Co., Ltd., Shenzhen

C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: Shenzhen City, Guangdong Province, 518040 Shennan Road No. 6009 Che Kung Temple Green Plaza building 37 layer

Patentee after: Shenzhen Salubris Pharmaceuticals Co., Ltd.

Address before: 1901 room 6007, exhibition center, 518040 Shennan Road, Guangdong, Shenzhen, Futian District

Patentee before: Shenzhen Salubris Pharmaceuticals Co., Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060329

Termination date: 20191223